BNTX logo
BNTX
BioNTech

Long-term Secular Trends Will Unlock mRNA And Oncology Breakthroughs

AN
AnalystHighTarget
AnalystHighTarget
Not Invested
Consensus Narrative from 20 Analysts
Published
13 Apr 25
Updated
23 Jul 25
AnalystHighTarget's Fair Value
US$172.75
35.4% undervalued intrinsic discount
23 Jul
US$111.66
Loading
1Y
38.2%
7D
4.0%

Author's Valuation

US$172.7

35.4% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates4

Shared on07 May 25
Fair value Increased 13%

Read more

Shared on30 Apr 25
Fair value Decreased 1.07%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 9.72%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25
Fair value Decreased 18%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more